Laurence Baker, D.O., is a medical oncologist at the University of Michigan Comprehensive Cancer Center. He also serves as Professor of Medicine, Associate Chief of the Division of Hematology/Oncology, and Deputy Director for Clinical Research. Dr. Baker is the Associate Chairman of the Southwest Oncology Group and the Associate Leader for the Sarcoma Disease Site Team of the American College of Surgeons’ Commission on Cancer. With over 30 years of sarcoma experience, Dr. Baker considers his particular strength to be establishing multi-disciplinary care as the standard for sarcoma treatment.
George Demetri, M.D., is a medical oncologist at the Dana-Farber Cancer Institute, where he also serves as the Director for the Center for Sarcoma and Bone Oncology, and an Associate Professor of Medicine at the Harvard Medical School. Dr. Demetri also chairs the Sarcoma Clinical Practice Guidelines Committee of the National Comprehensive Cancer Network and is the founder and editor of a wonderful web resource, Sarcoma.Net. He recently led the Phase II studies of Gleevec for GIST, as well as early studies of ET-743, the drug derived from sea squirts that has shown some success in treating some soft-tissue sarcomas. Dr. Demetri feels that his particular strength is new drug development based on rational scientific targets.
Burton Eisenberg, M.D., F.A.C.S., is a surgical oncologist at Dartmouth-Hitchcock Medical Center in Lebanon, NH. He serves as Deputy Director of the Norris Cotton Cancer Center and is a Professor of Surgery at the Geisel School of Medicine at Dartmouth. Doctor Eisenberg chaired the Sarcoma Working Group Committee of the Radiation Oncology Group (RTOG) until 2011. He has special interest in both clinical and translational research in soft tissue sarcomas. In addition, he is the author or co-author of a number of publications and book chapters related to the management of soft tissue sarcomas.
Charles Forscher, M.D., is a medical oncologist at Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute and Assistant Clinical Professor at the UCLA School of Medicine. His areas of expertise include chemotherapy for soft tissue and bone sarcomas as apart of a combined modality approach to sarcoma management. Dr. Forscher’s particular strength lies in utilizing nonadjuvant chemotherapy to gain a better understanding of the response of particular sarcomas to treatment. Dr. Forscher limits his practice to the study and treatment of sarcomas and has more than twenty years of experience in the field. His referral base is nationwide.
Robert Goldsby, M.D. has a strong clinical interest in pediatric sarcomas, particularly osteosarcomas and late effects of childhood cancer. His clinical research focuses on developing new therapies for children, adolescents and young adults with high-risk sarcomas. He is currently the principle investigator developing the next Children’s Oncology Group clinical trial for metastatic osteosarcoma. Additionally, he is working with Dr. Richard O’Donnell and others to establish a comprehensive and interdisciplinary Musculoskeletal Tumor Service at UCSF. He also participates in a number of investigations examining the late effects of cancer therapy. He has assumed the responsibilities as the institutional principal investigator for the national Children’s Cancer Survivorship Study and is a contributing member of the Children’s Oncology Group Long-Term Follow-up Guidelines Task Force. Recently, UCSF has established the Childhood Cancer Survivorship Program which serves to provide care, education and research for survivors of childhood cancer.
Linda Granowetter, M.D., is a pediatric oncologist at the Babies & Children’s Hospital of New York and Director of Pediatric Oncology at the Herbert Irving Child and Adolescent Cancer Center. Dr. Granowetter is also an Associate Professor of Clinical Pediatrics at Columbia University, College of Physicians and Surgeons. She is a member of the Columbia Presbyterian Cancer Center Sarcoma Group and the Children’s Oncology Group Ewing’s Sarcoma Subcommittee. Dr. Granowetter is a clinician who contributes to the treatment of sarcoma with her daily work and translates new biologic advances into appropriate and meaningful clinical trials.
Richard J. O’Donnell, M.D., is the Chief of the Orthopaedic Oncology Service as the UCSF Helen Diller Family Comprehenisive Cancer Center. He is a Professor of Clinical Orthopaedic Surgery at UCSF and Director of the UCSF Sarcoma Program. He has been a Sarcoma Alliance Medical Advisory Board member since 2002. He is also a member of the National Comprehensive Cancer Network’s Bone Cancer Panel, Sarcoma Cancer Panel and the Gastrointestinal Stromal Tumor Consensus Group. Doctor O’Donnell has done extensive research in the area of pediatric sarcomas and limb-salvage procedures. He is a member of the Connective Tissue Oncology Society, the Musculoskeletal Tumor Society, and the International Society on Limb Salvage. He is the Founder of the Orthopaedic Surgical Osseointegration Society.
To learn more visit his personal web page at:
Brian O’Sullivan, M.D., is a radiation oncologist at the Princess Margaret Hospital in Toronto, Ontario. In the Department of Radiation Oncology, he serves as the Academic Chair of Head and Neck Oncology, as the Head of Sarcoma and Skin Sections, and is an Assistant Professor. Dr. O’Sullivan has expertise in the area of local management issues, especially radiotherapy for all sites of disease except gynecological sarcomas and GIST. He is uniquely experienced in limb function outcome assessment and in the use of pre-operative radiotherapy.
Raphael Pollock, M.D., Ph.D., F.A.C.S., is a surgical oncologist and Head of the Division of Surgery at the University of Texas M.D. Anderson Cancer Center. He also serves as Professor and Chairman of the Department of Surgical Oncology and as Professor in the Department of Cancer Biology. Dr. Pollock is the Chairman of the National Sarcoma Patterns of Care Committee of the American College of Surgeons’ Commission on Cancer. He is also the Chairman of the Soft Tissue Sarcoma Task Force of the American Joint Committee on Cancer, Co-Chairman of the Sarcoma Committee of the National Cancer Center Coalition, and Chair of the Sarcoma Subcommittee of the Society of Surgical Oncology.
Sharon Weiss, M.D., is a pathologist at Emory University Hospital, where she serves as the Acting Chair of the Department of Pathology and Laboratory Medicine and as Professor. She also serves as Director of Anatomic Pathology and of Soft Tissue Pathology. Dr. Weiss previously served as President of the United States and Canadian Academy of Pathology. She co-authored the leading clinical reference on tumors of the muscle, fat, and connective tissues.